Skip to main content
SpringerLink
Log in

Neuroimaging Techniques

CT, MRI, SPECT, PET

  • Chapter
Alzheimer’s Disease

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 348 Accesses

Abstract

Even with current clinical diagnostic methods, there continues to be considerable difficulty in diagnosing neurodegenerative diseases with confidence. Neuroimaging has the potential to improve dementia diagnosis further by going beyond its traditional role of simply excluding mass lesions and stroke and helping to distinguish specific dementing diseases. Considerable research indicates that magnetic resonance imaging (MRI) can identify early structural changes caused by Alzheimer’s disease (AD). MRI also can identify Creutzfeldt-Jakob disease (CJD) and frontotemporal dementia (FTD). Furthermore, molecular neuroimaging techniques reveal characteristic focal abnormalities in neurodegenerative diseases that are unrecognized by other methods. Although further research is needed to understand how the clinical potential of imaging can be optimally exploited, there is now sufficient experience to suggest ways in which neuroimaging can be incorporated into everyday diagnostic and treatment decisions about dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Price, T.R. et al.: Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1997; 28: 1158–1164.

    Article  PubMed  CAS  Google Scholar 

  2. Vermeer, S.E. et al.: Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33: 21–25.

    Article  PubMed  Google Scholar 

  3. Chimowitz, M.I. et al.: Periventricular lesions on MRI. Facts and theories. Stroke 1989; 20: 963–967.

    Article  PubMed  CAS  Google Scholar 

  4. De Groot, J.C. et al.: Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000; 47: 145–151.

    Article  PubMed  Google Scholar 

  5. DeCarli, C. et al.: Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001; 58: 643–647.

    Article  PubMed  CAS  Google Scholar 

  6. Mungas, D. et al.: MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer’s disease. Neurology 2001; 57: 2229–2235.

    Article  PubMed  CAS  Google Scholar 

  7. Rosen, W.G. et al.: Pathological verification of ischemic score in differentiation of dementia. Ann Neurol 1980; 7: 486–488.

    Article  PubMed  CAS  Google Scholar 

  8. Roman, G.C. et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–260.

    Article  PubMed  CAS  Google Scholar 

  9. Longstreth, W.T. et al.: Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998; 55: 1217–1225.

    Article  PubMed  Google Scholar 

  10. Fein, G. et al.: Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000; 55: 1626–1635.

    Article  PubMed  CAS  Google Scholar 

  11. Gearing, M. et al.: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology 1995; 45: 461–466.

    Article  PubMed  CAS  Google Scholar 

  12. Scheltens, P. et al.: Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1: 13–21.

    Article  PubMed  Google Scholar 

  13. Visser, P.J. et al.: Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002; 72: 491–497.

    PubMed  CAS  Google Scholar 

  14. Finkenstaedt, M. et al.: MR imaging of Creutzfeldt-Jakob disease. Radiology 1996; 199: 793–798.

    PubMed  CAS  Google Scholar 

  15. Na, D.L. et al.: Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol 1999; 56: 951–957.

    Article  PubMed  CAS  Google Scholar 

  16. Schroter, A. et al.: Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000; 57: 1751–1757.

    Article  PubMed  CAS  Google Scholar 

  17. Mittal, S. et al.: Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002; 59: 128–134.

    Article  PubMed  Google Scholar 

  18. Kropp, S. et al.: The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol 1999; 56: 55–61.

    Article  PubMed  CAS  Google Scholar 

  19. Zeidler, M. et al.: The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355: 1412–1418.

    Article  PubMed  CAS  Google Scholar 

  20. Phelps, M.E. et al.: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371–388.

    Article  PubMed  CAS  Google Scholar 

  21. Messa, C. et al.: High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET. J Nuclear Med 1994; 35: 210–216.

    CAS  Google Scholar 

  22. Kwan, L.T. et al.: Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol 1999; 56: 809–814.

    Article  PubMed  CAS  Google Scholar 

  23. Foster, N.L.; Minoshima, S.; Kuhl, D.E.: Brain imaging in Alzheimer disease. In: Terry, R.D. et al. (eds.): Alzheimer Disease. 2nd ed. Raven Press, New York, 1999: 67–93.

    Google Scholar 

  24. Minoshima, S. et al.: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997; 42: 85–94.

    Article  PubMed  CAS  Google Scholar 

  25. Foster, N.L. et al.: Inter-rater reliability and diagnostic accuracy of FDG-PET is superior to clinical history and examination in dementia. Neurobiol Aging 2002; 23: 5353.

    Google Scholar 

  26. Meguro, K. et al.: Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer’s disease. Brain 1999; 122: 1519–1531.

    Article  PubMed  Google Scholar 

  27. Meguro, K. et al.: Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer’s disease: a PET/MRI correlative study. J Neurol Neurosurg Psychiatry 2001; 71: 315–321.

    Article  PubMed  CAS  Google Scholar 

  28. Koss, E. et al.: Differences in lateral hemispheric asymmetries of glucose utilization between early-and late-onset Alzheimer-type dementia. Am J Psychiatry 1985; 142: 638–640.

    PubMed  CAS  Google Scholar 

  29. Foster, N.L. et al.: Cortical abnormalities in Alzheimer’s disease. Ann Neurol 1984; 16: 649–654.

    Article  PubMed  CAS  Google Scholar 

  30. Haxby, J.V. et al.: Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990; 47: 753–760.

    Article  PubMed  CAS  Google Scholar 

  31. Imamura, T. et al.: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett 1997; 235: 49–52.

    Article  PubMed  CAS  Google Scholar 

  32. Albin, R.L. et al.: Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47: 462–466.

    Article  PubMed  CAS  Google Scholar 

  33. Ishii, K. et al.: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998; 51: 125–130.

    Article  PubMed  CAS  Google Scholar 

  34. Miller, B.L. et al.: Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia 1993; 4: 204–213.

    PubMed  CAS  Google Scholar 

  35. Mazziotta, J.C. et al.: Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med 1987; 316: 357–362.

    Article  PubMed  CAS  Google Scholar 

  36. Foster, N.L. et al.: Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988; 24: 399–406.

    Article  PubMed  CAS  Google Scholar 

  37. Eidelberg, D. et al.: The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991, 54: 856–862.

    Article  PubMed  CAS  Google Scholar 

  38. Knopman, D.S. et al.: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–1153.

    Article  PubMed  CAS  Google Scholar 

  39. Hoffman, J.M. et al.: Interpretation variability of 18FDG-positron emission tomography studies in dementia. Invest Radiol 1996; 31: 316–322.

    Article  PubMed  CAS  Google Scholar 

  40. Lim, A. et al.: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. JAm Geriatr Soc 1999; 47: 564–569.

    CAS  Google Scholar 

  41. Hoffman, J.M. et al.: FDG-PET imaging in patients with pathologically verified dementia. J Nuclear Med 2000; 41: 1920–1928.

    CAS  Google Scholar 

  42. Silverman, D.H.S. et al.: Positron emission tomography in evaluation of dementia: regional brain metabolism and longterm outcome. JAMA 2001; 286: 2120–2127.

    Article  PubMed  CAS  Google Scholar 

  43. Hsu, Y.Y. et al.: Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatr Neurol 2001; 14: 145–166.

    Article  CAS  Google Scholar 

  44. Bookheimer, S.Y. et al.: Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000; 343: 450–456.

    Article  PubMed  CAS  Google Scholar 

  45. Kuhl, D.E. et al.: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000; 48: 391–395.

    Article  PubMed  CAS  Google Scholar 

  46. Shoghi-Jadid, K. et al.: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatr 2002; 10: 24–35.

    Google Scholar 

  47. Mathis, C.A. et al.: A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295–298.

    Article  PubMed  CAS  Google Scholar 

  48. Fox, N.C. et al.: Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain 1996; 119: 2001–2007.

    Article  PubMed  Google Scholar 

  49. Small, G.W. et al.: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 2000; 97: 6037–6042.

    Article  PubMed  CAS  Google Scholar 

  50. Reiman, E.M. et al.: Preclinical evidence of Alzheimer’s disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752–758.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Norman L. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Oklahoma College of Medicine, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  2. Alzheimer’s Disease Research Unit, St. John Medical Center, Tulsa, OK, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  3. Tulsa, OK, USA

    Brigitte Zoeller Richter DiplPharm (Pharmacist, Publicist) (Pharmacist, Publicist)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Foster, N.L. (2004). Neuroimaging Techniques. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-661-4_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4485-9

  • Online ISBN: 978-1-59259-661-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation